Moody's revises ANI Pharmaceuticals' outlook to positive; affirms B2 CFR
Moody's Investors Service ("Moody's") affirmed ANI Pharmaceuticals, Inc.'s ("ANI") ratings including the B2 Corporate Family Rating (CFR), B2-PD Probability of Default Rating (PDR), and the B2 rating of the senior secured bank credit facilities. ANI's Speculative Grade Liquidity Rating is unchanged ...ANI Pharmaceuticals is a pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company's products include, among others: Arimidex, which is used for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; Erythromycin Ethylsuccinate, which is used to treat infections caused by susceptible strains of designated organisms for selected diseases; Diphenoxylate Hydrochloride and Atropine Sulfate, which is used as an adjunctive therapy in the management of diarrhea; and Etodolac, which is used to treat mild to moderate pain caused by osteoarthritis and rheumatoid arthritis.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.